Theralase announced its 2012 year-end financial results, reporting a 10% reduction in total revenue to $1.8 million compared to 2011, primarily due to a decrease in laser sales in the US and internationally. Research and development costs increased 15% to $873,335 as the company focused on developing its next-generation laser and photo dynamic compound cancer destruction technology. The net loss for 2012 was $1.5 million, up from $1.45 million in 2011, due to increases in stock-based compensation and R&D costs. Theralase is preparing to launch its new TLC-2000 laser in 2013 and expects its photo dynamic compound bladder cancer treatment to be ready for human trials in 2014.

1. Press Release
Theralase Announces 2012 Year End Financials
Theralase Advances Therapeutic Laser and Cancer Destruction Technologies
Toronto, Ontario – May 1, 2013, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2012 financial
results today.
Total revenue for the twelve month period ended December 31, 2012 dipped slightly to $1,824,313 compared to
$2,027,058 for the same period in 2011, a 10% reduction, primarily due to a reduction in laser sales in the US and
internationally. In 2012, Theralase focused its efforts on laser sales in Canada for its Therapeutic Laser Technology
(TLT) Division and for accelerating the research and development of its patented cancer destruction platform for
its Photo Dynamic Therapy (PDT) Division.
Selling expenses decreased by 41%, to $626,380 for the twelve month period ended December 31, 2012 compared
to $1,060,288 for the same period in 2011. The percentage decrease was due to decreased spending on salaries,
marketing, advertising and travel related expenses, as more focus was paid to completing sales in Canada, than
abroad.
Administrative expenses increased from $1,028,431 for the twelve months ended December 31, 2011 to
$1,238,900 for the same period in 2012 representing an increase of 20%. The increase in administrative
expenditures was primarily due to increases in the costs associated with stock based compensation.
Research and development costs increased to $873,335 for the year ended December 31, 2012 compared to
$759,352 for the previous year, representing a 15% increase, due in part to the costs required to commercialize
the TLC-2000 biofeedback laser, but primarily due to research and development costs of the TLC-3000 Photo
Dynamic Compound (PDC) cancer and bacteria destruction technology.
The net loss for the year ended December 31, 2012 was $1,509,569, which included $322,915 of net non-cash
expenses (amortization, stock-based compensation expense, foreign exchange gain/loss, equipment write-off and
lease inducements) compared to a net loss in 2011 of $1,453,974, which included $74,921 of net non-cash
expenses. The increase in net loss is due to increases in the costs associated with stock based compensation,
commercialization of the patented TLC-2000 Biofeedback Therapeutic Laser due for launch in 2013 and primarily
due to the research and development of the TLC-3000 Photo Dynamic Compound cancer destruction technology
due for completion of the pre-clinical phase by 4Q2013.
Theralase has had many successes in 2012, specifically:
• Preclinical research that confirmed the complete destruction of subcutaneous (under the skin) colon
cancer tumours in mouse subjects, which were treated with the Theralase anti-cancer Photo Dynamic
Compound (PDC) technology, which have continued to thrive cancer-free for more than 1 year post-
treatment without any side effects.
• Bladder cancer named as the principal cancer target
• Theralase’s PDC was found to be 100% effective in destroying bladder cancer tumour cells
• Theralase PDCs have shown an ability to destroy Escherichia Coli (E. coli) and Listeria Monocytogenes
(Listeria) bacteria in vitro when light activated
• Theralase establishes laser distributors in the Middle East and China
• Addition of TENS (Transcutaneous Electrical Nerve Stimulation) on select laser models to allow additional
CPT billing codes for the US market
• Theralase's innovative anti-cancer PDC technology validated at major international conferences
• Theralase expands intellectual property portfolio with increased patent protection
• Renowned oncologist Dr. Michael Jewett joins Theralase's medical and scientific advisory board

2. Press Release
Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “The Company has completed
the research and development of its next generation, patented TLC-2000 Biofeedback Therapeutic Laser and is
now preparing for its launch in 4Q2013. In addition, Theralase has made great strides forward in the research and
development of its patented Photo Dynamic Compounds (PDCs), indicated for the destruction of specific cancerous
tumours. Our first target, bladder cancer, should be ready for human trials as early as 2014. In order to capitalize
on this state-of-the-art cancer destruction technology and dramatically increase shareholder value, Theralase is in
negotiations with strategic partners focused on the early commercialization of this ground breaking technology.”
About Theralase Technologies Inc.
Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed
laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and
effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and
wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and
viruses when light activated by Theralase’s proprietary laser technology.
The complete consolidated financial statements and MD&A for twelve months ending December 31, 2012 may be
viewed at www.theralase.com and www.sedar.com .
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-
looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any
obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information, please contact:
Roger Dumoulin-White,
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com